|
Technology
MSDx has negotiated Worldwide Exclusive rights to the
antibody technology developed by two hematology experts. A
blood sample is analyzed by a clinical or reference
laboratory to detect the presence of the Multiple Sclerosis
biomarker. MSDx uses an industry standard immunoassay
technology which will adapt to equipment platforms already
in-use by clinical laboratories.
MSDx utilizes a patented diagnostic antibody technology that
provides physicians a blood test for Multiple Sclerosis.
Simply stated, combining
the
MSDx reagent with a
patient’s blood provides a definitive and painless diagnosis
for Multiple Sclerosis. Figure 3 below provides a
representation of how the technology works when processed on
In-Vitro Diagnostic Equipment by a clinical reference or
hospital laboratory.
|
